Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia

Ibrutinib produces high response rates and durable remissions in Waldenström macroglobulinemia (WM) that are impacted by MYD88 and CXCR4(WHIM) mutations. Disease progression can develop on ibrutinib, although the molecular basis remains to be clarified. We sequenced sorted CD19(+) lymphoplasmacytic...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Blood
Prif Awduron: Xu, Lian, Tsakmaklis, Nicholas, Yang, Guang, Chen, Jiaji G., Liu, Xia, Demos, Maria, Kofides, Amanda, Patterson, Christopher J., Meid, Kirsten, Gustine, Joshua, Dubeau, Toni, Palomba, M. Lia, Advani, Ranjana, Castillo, Jorge J., Furman, Richard R., Hunter, Zachary R., Treon, Steven P.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: American Society of Hematology 2017
Pynciau:
Lymphoid Neoplasia
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7484977/
https://ncbi.nlm.nih.gov/pubmed/28235842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-01-761726
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg